DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RANITIDINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Ranitidine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000964	The Effect of Stomach Acid on Foscarnet	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	To see if ranitidine, by reducing stomach acidity, can enhance the effectiveness of foscarnet, by making foscarnet more available to the body. Foscarnet is an antiviral compound. Laboratory studies have shown it to be active against HIV. However, only 12 - 22 percent of an oral foscarnet dose is absorbed by the body. Ranitidine suppresses gastric acid output, increasing gastric pH. Thus by increasing gastric pH (decreasing stomach acidity), less foscarnet is expected to be decomposed or broken down in the stomach. Thus, more foscarnet should be absorbed into the body.
NCT00002106	A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3	Completed	Glaxo Wellcome	Phase 2	To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
NCT00037570	Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 2	This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients. Patients will receive either intravenous pantoprazole (one of two regimens) or ranitidine (the comparator) within 2 hours of successful hemostasis and administration will continue for 72 hours after hemostasis.

Clinical Trial Conditions for Ranitidine Hydrochloride

Condition Name

Condition Name for Ranitidine Hydrochloride
Intervention	Trials
Healthy	6
Dyspepsia	4
Gastroesophageal Reflux Disease (GERD)	3

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ranitidine Hydrochloride
Intervention	Trials
Ulcer	7
Pain, Postoperative	5
Gastroesophageal Reflux	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ranitidine Hydrochloride

Trials by Country

Trials by Country for Ranitidine Hydrochloride
Location	Trials
United States	74
China	18
Korea, Republic of	12
Egypt	10
Taiwan	7

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ranitidine Hydrochloride
Location	Trials
California	11
Texas	8
Florida	5
Illinois	4
Pennsylvania	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ranitidine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ranitidine Hydrochloride
Clinical Trial Phase	Trials
Phase 4	28
Phase 3	16
Phase 2	23

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ranitidine Hydrochloride
Clinical Trial Phase	Trials
Completed	53
Recruiting	17
Not yet recruiting	9

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ranitidine Hydrochloride

Sponsor Name

Sponsor Name for Ranitidine Hydrochloride
Sponsor	Trials
AstraZeneca	6
Mansoura University	5
Eisai Inc.	3

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ranitidine Hydrochloride
Sponsor	Trials
Other	96
Industry	38
NIH	4

Export unavailable in trial.
Subscribe for complete access.